African Health Sciences
Makerere University Medical School
Vol. 16, No. 3, 2016, pp. 766-771
Bioline Code: hs16097
Full paper language: English
Document type: Research Article
Document available free of charge
African Health Sciences, Vol. 16, No. 3, 2016, pp. 766-771
© Copyright 2016 - African Health Sciences
Association of interleukin 17 / angiotensin II with refractory hypertension risk in hemodialysis patients.|
Wang,Zebin; Shi,Wei; Liang,Xinling; Wang,Wenjian & Liang,Jianbo
Objective: The study was performed to investigate the association of interleukin 17 (IL 17) or angiotensin II (Ang II) with
refractory hypertension risk in hemodialysis patients.
Methods: Ninety hemodialysis patients were enrolled into this study, and those with hypertension were divided into two groups.
The Easy-to-Control Hypertension group (ECHG) had fifty patients, while the refractory hypertension group (RHG) had forty
patients. Twenty healthy individuals were recruited as the control group. IL17 and Ang II were determined using a human IL 17
/ Ang II enzyme-linked immunosorbent assay kit. Serum IL 17 and Ang II concentrations in RHG patients were higher than
those in ECHG patients.
Results: Serum IL 17 and Ang II concentrations in both patient groups were higher than those in the control group. Linear
regression analysis showed a positive correlation between IL 17 and Ang II. In multivariate regression analysis, we found that
IL17 and Ang II were associated with refractory hypertension risk in hemodialysis patients.
Conclusion: IL17 and Ang II were associated with refractory hypertension risk in hemodialysis patients. There was also a positive
correlation between IL 17and Ang II.
Interleukin 17; Angiotensin II; refractory hypertension; hemodialysis